Kuros starts Phase II clinical trial in bone regeneration
Kuros reaches key milestone in its collaboration with Baxter
Kuros, a biotechnology company that develops novel biologics and biomaterials for localised therapy, announced that it has started a Phase II clinical trial in tibial plateau fractures as part of its collaboration with Baxter in hard and soft tissue repair. The Phase II clinical trial will be conducted by Kuros and aims to evaluate the safety and efficacy of the product.
Kuros' product in this indication utilises Kuros' technology for binding proprietary biologics within Baxter's fibrin-based biomatrix, TISSEEL Fibrin Sealant, to create a bioactive bone graft substitute for in-situ healing of long bone fractures. The product is injected directly at the fracture site, where it forms a solid fibrin composite that matches the shape of the fracture. According to the company, the product promotes bone growth through the release upon cellular demand of a modified version of a naturally occurring bone-forming molecule bound to the fibrin matrix.
Kuros entered into a major licence & collaboration agreement with Baxter Healthcare in 2005. The collaboration covers the development of a number of biological combination products targeted at certain skin and orthopaedic indications.
Other news from the department research and development
